Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Resolution Crystallization. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN112707901A reveals a cost-effective resolution method for moxifloxacin side chains using gulonic acid, offering >98% ee and simplified manufacturing for reliable API intermediate supply.
Patent CN102264715B reveals a scalable cinchonidine salt resolution process for HCV inhibitors, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Advanced acetylation-crystallization method for D-Pantolactone resolution. Delivers 99.5% optical purity with significant cost reduction and stable supply chain capabilities.
Patent CN106749177A details a novel tartaric acid purification method for SYR-322, ensuring high purity and cost reduction in API manufacturing for global supply chains.
Patent CN101883486B reveals non-chromatographic resolution. Enables cost reduction in pharmaceutical intermediate manufacturing via crystallization.
Patent CN107011228B details a novel chiral resolution process for Clemastine Fumarate ensuring high purity and scalable manufacturing for global pharmaceutical supply chains.
Patent CN101501000B details a novel purification process for Montelukast using chiral amine salts, offering high optical purity and cost reduction in pharmaceutical intermediate manufacturing without chromatography.
Patent CN104628720A offers high purity moxifloxacin hydrochloride refining. Enhances supply chain reliability and cost reduction in pharmaceutical manufacturing.
Patent CN114685558A reveals a high-yield preparation method for Remdesivir intermediate Compound I, offering significant cost reduction and supply chain reliability for global API manufacturers.
Patent CN102757367A details a cost-effective splitting process for DL-benzene ethyl sulfonic acid using L-HPG, offering high purity and supply chain stability for pharmaceutical intermediates.
Patent CN105218428A analysis reveals high purity Apremilast synthesis route. Delivers cost reduction and supply chain reliability for global pharma manufacturing partners seeking scalable API solutions.
Patent CN103224467A details a cost-effective resolution method for (-)-Huperzine A, achieving >99.5% purity and significantly reducing manufacturing costs for pharmaceutical applications.
Novel water-based resolution method for R-tetrahydropapaverine ensures high purity and cost efficiency for cisatracurium besilate manufacturing.
Patent CN113242854B reveals novel chiral resolution for S-IOBA. Enhances supply chain reliability and reduces manufacturing costs for agrochemical intermediates significantly.
Advanced resolution technology for Edoxaban precursor ensuring >99% ee. Optimized for cost-effective API manufacturing and reliable supply chain continuity.
Patent CN102249998A reveals a high-yield synthesis route for Cisatracurium Besylate, offering superior purity and cost-effective manufacturing for pharmaceutical supply chains.
Patent CN115850115B reveals high-purity Ruxolitinib intermediate synthesis. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing partners.
Advanced purification process for tenofovir prodrug ensuring high purity. Cost-effective supply chain solutions for pharmaceutical intermediates. Reliable manufacturing partner for global pharmaceutical companies seeking scalable synthesis routes.
Patent CN111763150B reveals a novel L-glutamic acid resolution method for high-purity sertraline, offering significant cost reduction and supply chain reliability for global buyers.
Patent CN107674072B reveals a scalable resolution method for dihydropyrimidine intermediates using L-tartaric acid, offering superior optical purity and cost-effective manufacturing for pharmaceutical supply chains.